Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Retinal function after intravitreal injection of autologous bone marrow-derived mesenchymal stromal cells in advanced glaucoma.

Tytuł:
Retinal function after intravitreal injection of autologous bone marrow-derived mesenchymal stromal cells in advanced glaucoma.
Autorzy:
Vilela CAP; Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - 12º. Andar, Ribeirão Preto, São Paulo, 14049 - 900, Brazil.
Messias A; Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - 12º. Andar, Ribeirão Preto, São Paulo, 14049 - 900, Brazil. .
Calado RT; Department of Medical Images, Hematology and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Siqueira RC; Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - 12º. Andar, Ribeirão Preto, São Paulo, 14049 - 900, Brazil.
Silva MJL; Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - 12º. Andar, Ribeirão Preto, São Paulo, 14049 - 900, Brazil.
Covas DT; Department of Medical Images, Hematology and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Paula JS; Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - 12º. Andar, Ribeirão Preto, São Paulo, 14049 - 900, Brazil.
Źródło:
Documenta ophthalmologica. Advances in ophthalmology [Doc Ophthalmol] 2021 Aug; Vol. 143 (1), pp. 33-38. Date of Electronic Publication: 2021 Jan 19.
Typ publikacji:
Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: Dordrecht : Kluwer
Original Publication: s'-Gravenhage [etc.]
MeSH Terms:
Glaucoma*
Glaucoma, Open-Angle*
Mesenchymal Stem Cells*
Bone Marrow ; Electroretinography ; Humans ; Intravitreal Injections
References:
Johnson TV, DeKorver NW, Levasseur VA et al (2014) Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome. Brain 137(2):503–519. (PMID: 10.1093/brain/awt292)
Park SS, Moisseiev E, Bauer G et al (2017) Advances in bone marrow stem cell therapy for retinal dysfunction. Prog Retin Eye Res 56:148–165. (PMID: 10.1016/j.preteyeres.2016.10.002)
Harrell CR, Fellabaum C, Arsenijevic A, Markovic BS, Djonov V, Volarevic V (2019) Therapeutic potential of mesenchymal stem cells and their secretome in the treatment of glaucoma. Stem Cells Int 2019:7869130. (PMID: 319494416948292)
Castro A, Du Y (2019) Trabecular meshwork regeneration—a potential treatment for glaucoma. Curr Ophthalmol Rep 7(2):80–88. (PMID: 10.1007/s40135-019-00203-2)
Roubeix C, Godefroy D, Mias C et al (2015) Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma. Stem Cell Res Ther 6:177. (PMID: 10.1186/s13287-015-0168-0)
Mead B, Hill LJ, Blanch RJ et al (2016) Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. Cytotherapy 18(4):487–496. (PMID: 10.1016/j.jcyt.2015.12.002)
Vilela CAP, Souza LEB, Siqueira RC, Calado RT, Covas DT, Paula JS (2018) Ex vivo evaluation of intravitreal mesenchymal stromal cell viability using bioluminescence imaging. Stem Cell Res Ther 9(1):155. (PMID: 10.1186/s13287-018-0909-y)
McCulloch DL, Marmor MF, Brigell MG et al (2015) ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130(1):1–12. (PMID: 10.1007/s10633-014-9473-7)
Tzameret A, Sher I, Belkin M et al (2014) Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. Exp Eye Res 118:135–144. (PMID: 10.1016/j.exer.2013.10.023)
Mead B, Amaral J, Tomarev S (2018) Mesenchymal stem cell-derived small extracellular vesicles promote neuroprotection in rodent models of glaucoma. Invest Ophthalmol Vis Sci 59(2):702–714. (PMID: 10.1167/iovs.17-22855)
Kuriyan AE, Albini TA, Townsend JH et al (2017) Vision loss after intravitreal injection of autologous “stem cells” for AMD. N Engl J Med 376(11):1047–1053. (PMID: 10.1056/NEJMoa1609583)
Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A (2014) Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res 40:16–34. (PMID: 10.1016/j.preteyeres.2013.12.006)
Contributed Indexing:
Keywords: ERG; Electroretinogram; Glaucoma; Mesenchymal stem cells
Molecular Sequence:
ClinicalTrials.gov NCT02330978
Entry Date(s):
Date Created: 20210120 Date Completed: 20211020 Latest Revision: 20220531
Update Code:
20240105
DOI:
10.1007/s10633-021-09817-z
PMID:
33469852
Czasopismo naukowe
Purpose: To report electroretinographic (ERG) findings in advanced glaucoma treated with a single intravitreal injection of bone marrow-derived mesenchymal stem cells (MSCs).
Methods: Intravitreal injection of autologous MSCs (1 × 10 6 cells) was performed in 2 eyes from 2 patients with open-angle glaucoma in advanced stage of optic neuropathy (ClinicalTrials.gov, NCT02330978, 01.05.2015): cup/disk ratio worse than 0.9, visual field mean deviation index lower than - 15 dB, visual acuity of light perception, but controlled intraocular pressure. ERG tests were recorded at baseline and week 1, 4 and 48 after injection, using DTL electrodes following the ISCEV standard: After dark adaptation, ERG was elicited using white flashes of 0.01 cd.s/m 2 and 3.0 cd.s/m 2 , followed by 10-min light adaptation (30 cd/m 2 ) and stimuli of 3.0 cd.s/m 2 and 30 Hz flicker.
Results: Patients did not show improvement on visual acuity or visual field after treatment. At baseline, ERG responses showed typical findings for advanced glaucoma, with a- and b-wave amplitude and latency within normative range, but reduced photopic negative responses. No noteworthy changes were observed on ERG responses for both cases up to 1 week after treatment, but at day 15, one patient showed retinal detachment with proliferative vitreoretinopathy and was removed from the trial. The other patient kept ERG responses stable throughout study period.
Conclusion: Although no ERG response changes were observed after MSCs injection in one case, the complication observed on the second one, along with the lack of visual function improvement, warrants further studies involving modified MSCs to treat ocular disorders, including glaucoma.
Trial Registration: ClinicalTrials.gov, NCT02330978- missed in pdf.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies